Semaglutide vs Tirzepatide: Which GLP-1 Is Better for Weight Loss in 2026?

If you're exploring GLP-1 medications for weight loss, you've almost certainly run into the semaglutide vs tirzepatide debate. Both medications have generated enormous attention, and for good reason — they represent a genuine breakthrough in how we treat obesity. But they're not the same drug, and choosing between them matters.

Semaglutide is the active ingredient in Wegovy and Ozempic, developed by Novo Nordisk. Tirzepatide is the active ingredient in Zepbound and Mounjaro, developed by Eli Lilly. Both are injectable medications taken once weekly. Both have been shown to produce significant weight loss in clinical trials. But they target different receptors, produce different magnitudes of weight loss, and have somewhat different side effect profiles.

In this guide, we'll go through everything you need to know about both medications — including what the clinical trials actually showed, how the side effects compare, what they cost in 2026 (including compounded options), and who might be a better candidate for each one. For deeper dives on each medication individually, see our semaglutide guide and tirzepatide guide.

How They Work: GLP-1 Only vs. GLP-1 + GIP

This is the fundamental difference between these two medications, and it's worth understanding even at a basic level. Both drugs mimic natural hormones that your gut produces after eating. These hormones — called incretins — help regulate blood sugar, slow digestion, and signal to your brain that you're full.

Think of it this way: semaglutide pulls one lever (GLP-1) very effectively. Tirzepatide pulls two levers (GLP-1 and GIP) simultaneously. The theory behind tirzepatide is that combining both incretin pathways produces a stronger overall effect on appetite, blood sugar, and weight loss. The clinical data so far supports that theory — but both medications are remarkably effective compared to anything that came before them.

It's also worth noting that GIP's role in weight loss is still being actively studied. For years, researchers weren't sure whether activating GIP receptors would help or hurt weight loss efforts. Tirzepatide's clinical success has largely settled that debate, but the exact mechanisms by which GIP contributes to weight loss are still being mapped out.

Weight Loss Results: What the Clinical Trials Show

Let's get to the numbers everyone wants to see. The weight loss data for both medications comes from large, well-designed clinical trials: the STEP trials for semaglutide and the SURMOUNT trials for tirzepatide.

The headline: tirzepatide produces more weight loss than semaglutide at the highest doses. At the maximum dose of 15 mg, tirzepatide participants in SURMOUNT-1 lost an average of about 22% of their body weight, compared to about 15% with semaglutide 2.4 mg in STEP 1. That's a meaningful difference — for someone weighing 220 pounds, it's the difference between losing roughly 33 pounds (semaglutide) and 48 pounds (tirzepatide).

However, there are important caveats. These were different trials with different patient populations, so direct comparison has limitations. The semaglutide dose used in trials (2.4 mg) is a fixed maximum, while tirzepatide has three dose levels (5, 10, and 15 mg). And individual variation within both trials was enormous — some semaglutide patients lost more weight than some tirzepatide patients, and vice versa.

A head-to-head trial (SURMOUNT-5) directly comparing tirzepatide to semaglutide has confirmed tirzepatide's advantage, with tirzepatide 15 mg producing approximately 47% greater weight reduction compared to semaglutide 2.4 mg over 72 weeks. This is the strongest evidence we have for tirzepatide's superiority in terms of raw weight loss numbers.

Head-to-Head Comparison Table

Here's a side-by-side look at the key differences between semaglutide and tirzepatide across the categories that matter most.

Side Effects: How Do They Compare?

Both semaglutide and tirzepatide share a similar side effect profile, which makes sense given that they both activate GLP-1 receptors. The most common side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation. These are most pronounced during the dose escalation phase and tend to improve as your body adjusts.

One pattern worth noting: while tirzepatide's trial data showed somewhat lower rates of individual GI side effects, the overall discontinuation rates due to adverse events were similar between both medications (approximately 4-7% in each). This suggests that while the specific side effect experiences may differ, overall tolerability is comparable.

Both medications carry warnings about potential pancreatitis, gallbladder problems, and thyroid C-cell tumors (based on animal studies). Neither should be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

The slow dose titration schedule used for both medications is specifically designed to minimize side effects. Rushing the dose increase is one of the most common mistakes patients make, and it almost always leads to worse GI symptoms. Patience during titration pays off significantly.

Pricing in 2026: Brand-Name and Compounded Options

Cost has been one of the biggest barriers to accessing GLP-1 medications, and it's an area where the landscape has shifted significantly. Here's where pricing stands as of May 2026.

The compounded market has made both medications dramatically more affordable. Compounded semaglutide is generally slightly cheaper than compounded tirzepatide, reflecting the difference in raw ingredient costs. But both are a fraction of brand-name pricing.

Insurance coverage varies enormously. Some plans cover Wegovy or Zepbound for weight loss with reasonable copays. Many don't. Medicare currently does not cover GLP-1 medications for weight loss (only for diabetes). If you're paying out of pocket, compounded versions from licensed telehealth providers are likely your most cost-effective path.

For a detailed breakdown of the most affordable semaglutide options, see our cheapest semaglutide online guide. You can also explore compounded tirzepatide options in our compounded tirzepatide reviews.

Who Should Choose Which?

This is the question everyone really wants answered, and the honest answer is: it depends on your individual circumstances. There's no universally “better” option. Here's a framework for thinking about it.

Ultimately, both semaglutide and tirzepatide are powerful, well-studied medications that represent a major advance in weight management. The “best” choice depends on your individual health profile, goals, budget, and preferences. This is a decision worth making with a knowledgeable healthcare provider who can assess your specific situation.

The Bottom Line

Both semaglutide and tirzepatide are exceptional weight loss medications. If you forced us to summarize the difference in one sentence: tirzepatide produces more weight loss on average, and semaglutide has a longer track record and is slightly cheaper in compounded form.

The good news is that you're not locked into either choice forever. Many patients start with one and switch to the other based on how they respond. Some providers even offer both options, making it easy to transition if needed.

If you're ready to start exploring your options, visit our provider comparison page to find licensed telehealth platforms that offer both medications. For detailed pricing, check out our cheapest semaglutide guide and compounded tirzepatide reviews.

We update this article as new clinical data and pricing information becomes available. Last updated May 6, 2026.

Frequently Asked Questions